| Eric Allan Van Orman, OD | |
|
3500 E Highway 101, Vision Center @ Wal-mart, Port Angeles, WA 98362-9148 | |
| (360) 452-6131 | |
| (360) 452-7950 |
| Full Name | Eric Allan Van Orman |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 35 Years |
| Location | 3500 E Highway 101, Port Angeles, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467552430 | NPI | - | NPPES |
| 2021947 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 1862 (Washington) | Primary |
| Provider Name | Eric A. Van Orman, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1447568415 PECOS PAC ID: 9739360363 Enrollment ID: O20110301001169 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.
Researchers at Moffitt Cancer Center say identifying and selecting participants for phase II cancer clinical trials from a centralized warehouse of patient-donated biological data expedites participant accrual, reduces trial size, saves money, and may speed test drugs through the drug development pipeline.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.
Tornier N.V., a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, reported sales of $57.6 million for the third quarter of 2011 compared to sales of $49.7 million for the third quarter of 2010, an increase of 16% as reported and 11% in constant currency.
A new study focused on the chronological changes in humoral and cell-mediated immune responses, during and after the BNT162b2 vaccine administration, among hospital workers of a national medical institution in Japan.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eric Allan Van Orman, OD 3500 E Highway 101, Vision Center @ Wal-mart, Port Angeles, WA 98362-9148 Ph: (360) 452-6131 | Eric Allan Van Orman, OD 3500 E Highway 101, Vision Center @ Wal-mart, Port Angeles, WA 98362-9148 Ph: (360) 452-6131 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.
Researchers at Moffitt Cancer Center say identifying and selecting participants for phase II cancer clinical trials from a centralized warehouse of patient-donated biological data expedites participant accrual, reduces trial size, saves money, and may speed test drugs through the drug development pipeline.
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.
Tornier N.V., a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, reported sales of $57.6 million for the third quarter of 2011 compared to sales of $49.7 million for the third quarter of 2010, an increase of 16% as reported and 11% in constant currency.
A new study focused on the chronological changes in humoral and cell-mediated immune responses, during and after the BNT162b2 vaccine administration, among hospital workers of a national medical institution in Japan.
› Verified 5 days ago
Dr. Kirk Thompson, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 811 Georgiana St, Port Angeles, WA 98362 Phone: 360-452-7661 Fax: 360-417-0254 | |
Thomas O Mccurdy Od Inc Ps Optometrist Medicare: Medicare Enrolled Practice Location: 504 E 8th St Ste A, Port Angeles, WA 98362 Phone: 360-457-1032 Fax: 360-452-9604 | |
George B Symonds, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1122 E Front St, Port Angeles, WA 98362 Phone: 360-457-1161 Fax: 360-457-2806 | |
Steven D. Lewis, Od, Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 901 S Lincoln St, Port Angeles, WA 98362 Phone: 360-452-9060 Fax: 360-457-1686 | |
John P Huard, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1026 E 1st St Ste A, Port Angeles, WA 98362 Phone: 360-452-2020 Fax: 360-452-8087 | |
Dr. Lawrence William Nivala, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 114 E 1st St, Port Angeles, WA 98362 Phone: 360-452-2361 Fax: 360-452-2362 | |
Angeles Vision Clinic, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 811 Georgiana St, Port Angeles, WA 98362 Phone: 360-452-7661 Fax: 360-417-0254 |